Filing Overview
Jasper Therapeutics, Inc. filed a Form 8-K covering events from June 2 through June 8, 2023. The filing reports an amendment to the company’s inducement equity plan, results of the 2023 annual meeting, and an amendment to the certificate of incorporation.
Material Corporate and Equity Changes
- The Compensation Committee increased the shares available under the 2022 Inducement Equity Incentive Plan by 2,500,000, from 3,000,000 to an aggregate of 5,500,000 shares.
- The plan may be used for equity awards to prospective employees or qualifying individuals being rehired, as a material inducement to employment. No other plan changes were reported.
- The plan amendment was adopted without stockholder approval under Nasdaq Listing Rule 5635(c)(4).
- Stockholders approved an amendment to the certificate of incorporation concerning Delaware law provisions for officer exculpation. The amendment became effective upon filing on June 8, 2023.
Annual Meeting Results
Approximately 83% of the 110,283,384 shares outstanding as of the April 14, 2023 record date were represented, totaling 91,903,816 shares.
- Director elections: Anna French and Judith Shizuru were elected as Class II directors to serve until the 2026 annual meeting.
- Auditor ratification: Stockholders ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2023, with 91,856,308 votes for, 37,101 against, and 10,407 abstentions.
- Officer exculpation amendment: Approved with 73,923,961 votes for, 7,116,389 against, 23,804 abstentions, and 10,839,662 broker non-votes.
Financial Metrics, Outlook, and Risks
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, financial guidance, operating outlook, or new business-risk disclosures. It also does not report a material financial contingency or unusual accounting item.
Investor Verification Items
- Review the amended and restated inducement plan to assess potential future equity dilution and compensation expense.
- Review the certificate amendment and related proxy statement for the scope and limitations of officer exculpation.
- Confirm the final director election and auditor-ratification results in subsequent corporate disclosures.
- Refer to the company’s periodic reports for cash runway, financing needs, clinical-program updates, and other operating risks not addressed in this 8-K.